PIOGLITAZONE HYDROCHLORIDE | A076798 | CHARTWELL RX SCIENCES LLC
| Petition | Type | Filed | Status | Petitioner |
|---|---|---|---|---|
Takeda Pharmaceuticals North America - Citizen Petition FDA-2007-P-0294 · 7 docket documents Takeda Pharmaceuticals North America filed this citizen petition requesting that the FDA not grant final approval to any abbreviated new drug application for generic pioglitazone hydrochloride unless the labeling includes information for both monotherapy and combination therapy use, consistent with | 505(q) | 2008-04-23 | Open | — |
Source: Regulations.gov. FDA citizen petitions matched by application number.
Highest NADAC/Unit
$0.1144
per ea
Lowest NADAC/Unit
$0.0689
per ea
Brand NDCs
0
Generic NDCs
3
| NDC Description | NADAC/Unit | Unit | Type | Generic NADAC | Effective |
|---|---|---|---|---|---|
| 62135080630PIOGLITAZONE HCL 45 MG TABLET | $0.1144 | EA | Generic | — | 2026-06-17 |
| 62135080530PIOGLITAZONE HCL 30 MG TABLET | $0.0895 | EA | Generic | — | 2026-06-17 |
| 62135080430PIOGLITAZONE HCL 15 MG TABLET | $0.0689 | EA | Generic | — | 2026-06-17 |
Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.
No patent or exclusivity listings for this strength.